RA2day: addressing today’s regulatory topics
Zwiers Regulatory Consultancy is organising RA2day on April 13th 2018.
Read more
Over 50 companies based at Pivot Park!
Recently the number of companies based at Pivot Park reached the milestone of 50!
Read more
New at Pivot Park – PharmaCytics
PharmaCytics offers a drug delivery solution, based on an advanced prodrug approach.
Read more
InnatOss and MediSapiens Receive EU Grant to Personalize Lyme Diagnostics
Recently the number of companies based at Pivot Park reached the milestone of 50!
Read more
New at Pivot Park – Sterk Schakelen
Sterk Schakelen is now a member of the Pivot Park Community.
Read more
New at Pivot Park – CheckMark Labrecruitment
Since December 1st Checkmark Labrecruitment is present at Pivot Park.
Read more
ImmunoPrecise to Acquire ModiQuest Research BV
IMMUNOPRECISE ANTIBODIES LTD. announces that it has signed a binding letter of intent with ModiQuest Research BV.
Read more
Anglo-Dutch research teams awarded Eurostars funding for a €1.1M project to develop a synthetic matrix for 3D organoid cell culture
Researchers at Maastricht University, Noviocell BV (based at Pivot Park) and Cell Guidance Systems Ltd are collaborating on an EU funded Eurostars project to develop fully-defined matrices for the 3D culture of organoids.
Read more
US FDA APPROVES ASTRAZENECA’S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to CALQUENCE® (acalabrutinib).
Read more